Prevacid Articles
Abbott earnings up as core sales grow
20 October 2003
Abbott earnings up as core sales grow
20 October 2003
Tokyo pharma stocks - week to Oct 13
20 October 2003
Tokyo pharma stocks - week to August 11
18 August 2003
Tokyo pharma stocks - week to July 28
4 August 2003
Tokyo pharma stocks - week to July 14
21 July 2003
Tokyo pharma stocks - week to June 16
23 June 2003
Crestor advisory panel raises fears of delay
26 May 2003
Colorado Medicaid sets eight-drug limit
5 May 2003
Takeda forecasts 315B yen profit in 2004
28 April 2003
High US co-pays "are driving PPI switches"
17 February 2003
Takeda to extend Takepron indications
10 February 2003
Tokyo pharma stocks - week to Jan 20
27 January 2003
Robust Takeda faces growing competition
13 January 2003
Pediatric labeling approved for Prevacid
12 August 2002
Tokyo pharma stocks - week to July 29
5 August 2002
Tokyo pharma stocks - week to July 15
22 July 2002
Japanese stock market - week to July 1
8 July 2002
World drug sales up 12% in year to Feb
22 April 2002
TAP gets fast-track review of Prevacid for children
22 April 2002
Nexium tops rival in GERD maintenance trial
4 March 2002
TAP seeks pediatric GERD label for Prevacid in USA
25 February 2002
Expensive new GERD drugs "actually more cost-effective"
28 January 2002
Tokyo pharma stocks - week to January 21
28 January 2002
TAP launches new Prevacid form in USA.
21 January 2002
World drug sales up 11% in year to Sept
3 December 2001
Nexium comparative data provides further boost to AstraZeneca
10 October 2001
World retail drug sales grew 11% in 12 months to July 2001, reports IMS
28 September 2001
Stock Commentary - Tokyo
19 July 2001
US state seniors Rx costs compared globally
18 July 2001
Japan pharma stocks - week to July 16
18 July 2001
Nexium makes strong start in USA
24 May 2001
Spanish patent piracy victory for Takeda
26 January 2001
Stock Commentary - Tokyo
25 January 2001
New indication for Prevacid in USA
7 December 2000
Japan's Takeda posts net profits up 52% helped by sales abroad
7 November 2000
Latest approvals from Japan's advisory board
25 October 2000
Stock Commentary Tokyo
12 October 2000
Takeda expands Irish plant
10 August 2000
Takeda benefits from strong US showing
24 May 2000
Wyeth's Zoton, NHS price reduced
4 May 2000
Yamanouchi's Gaster weathers patent expiry
20 January 2000
Stock Commentary Tokyo
19 August 1999
World's top-selling drugs; 2002 forecasts
13 August 1999
Wyeth slashes UK price of Zoton
2 July 1999
TAP Holdings posts strong sales growth
8 April 1999
-Abbott and Wyeth Laboratories launch HeliClear
18 February 1999
Takeda entering new phase of global expansion, says MSDW analyst
18 February 1999
AstraZeneca's Effect On Rest Of Pharma Sector
17 December 1998
US Majors Post Strong Earnings For 3rd Quarter
15 October 1998
Takeda Entering New Product Cycle
21 September 1998
Takeda Pharma Sets Up Swiss Subsidiary
11 September 1998
Stock Commentary Tokyo
2 September 1998
Canada Approves Ulcer Combination Therapy
27 August 1998
Analysts Backing Takeda As US Sales Grow
14 April 1998
Rx Drug Sales In USA Grew 12.6% Last Year
6 April 1998
Takeda, Diabetes Drive Japanese Blockbusters
19 February 1998
Strong Growth For US Drug Firms In 1997
28 January 1998
Eisai's Rabeprazole Debuts In Japan
5 January 1998
Ranbaxy/Dr Reddy's Collaborate On Antiulcerant Levant
14 November 1997
US 3rd Quarter Results Show Strong Growth
22 October 1997
Tokyo Stock Comment
25 September 1997
Laboratorios SALVAT R&D Policy Bears Fruit
21 August 1997
Solid Growth For US Firms Despite Strong $
24 July 1997
Prevacid OK'd For H pylori eradication
26 June 1997
Takeda To Set Up Subsidiary In The UK
25 June 1997
US 4th Qtr/Year-End Results See Strong Growth
27 January 1997
Turnover Rises 35% At Richter Gedeon
2 December 1996
Single-Digit Profits Growth For B-MS And W-L
5 August 1996
TOKYO STOCK COMMENT
29 July 1996
UK Industry Code of Practice Review
8 July 1996
Tokyo Stock Market
17 June 1996
Astra And Byk Gulden End PPI Dispute
17 June 1996
UK Prescription Medicine Code Of Practice Review
4 December 1995
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
